Harrow, Inc.
As of Oct 22, 2026, Harrow is in Stage 4, the downtrend phase, now in week 6 (since Sep 14, 2026). It closed at $28.15, 48.6% below its 52-week high and below its 200-day average, which is falling.
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is HROW early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
HROW among Drug Manufacturers - Specialty & Generic45th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …45 | HROW | Stage 4 · wk 6 | 33 | −16.2% |
Harrow: quick answers
What stage is Harrow in?
As of Oct 22, 2026, Harrow (HROW) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 14, 2026 and is in week 6. What the four stages mean
Is Harrow in an uptrend?
No. Harrow is in a Stage 4 downtrend. It trades 27.7% below its 200-day average, which is falling.
How far is Harrow from its 52-week high?
Harrow closed at $28.15 on Oct 22, 2026, 48.6% below its 52-week high of $54.80. Its 52-week low is $27.24.
How has Harrow performed over the past year?
As of Oct 22, 2026, Harrow is down 31.0% over the past year and down 43.6% so far in 2026.
Which sector and industry is Harrow in?
Harrow is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.